Wegovy 2.4mg pen

$354

Shipping from: European Union, United States
Shipping to: Worldwide
Escrow Protected: Auto-Finalized in 13 Days
Support email: shadowgatemarket@proton.me
SOLD: 379

110 in stock

Item will be shipped in 1 business day

This item is listed as an escrow. The order process is as follows

After ordering, all payments will be held by the Market(Admin) for up to 14 days. If the customer does not receive the product within this period, a full refund will be issued to the customers account. We only release payments to vendors/sellers after the customer confirms they have received their product. This escrow system ensures zero scams on the market. Happy shopping on ShadowGate Market, with zero tolerance for scams.

Description

Buy Wegovy 2.4mg x 1 pen (4 dose in pen).
No Prescription Need.

Wegovy is name of the brand of a new 2.4mg Semaglutide injection.
It’s licensed to treat chronic weight management in adults who are
considered obese and have at least one weight related health problem.
Wegovy contains the medicine Semaglutide which has been around for many
years. Semaglutide has been used to treat type 2 diabetes mellitus
(T2DM) and is also prescribed to help patients with weight loss.

Buy Wegovy 2.4mg x 1 pen (4 dose in pen).

This is for ONE pack of 2.4mg Wegovy containing 4 doses (ONE PER WEEK) to last 1 month.

Wegovy is a prescription medication containing the active ingredient
‘Semaglutide’ and has recently received approval from the National
Institute for Health and Care Excellence (NICE) for patients who meet
eligibility criteria, including carrying excess weight as an effective
weight loss drug.

The same active ingredient, Semaglutide, is found in existing medical
products including Ozempic and Rybelsus, which are currently only
approved/licensed for use in managing patients with type 2 diabetes, but
both are often prescribed for weight management.

Reviews

There are no reviews yet.

Be the first to review “Wegovy 2.4mg pen”
No more offers for this product!

General Inquiries

There are no inquiries yet.